Τίτλος:
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas
Περίληψη:
Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on the GO29365 phase IIb trial. Real-life data with Pola are extremely limited. We report the outcomes of 61 Greek patients, who received Pola-(B)R mainly within a compassionate use program. Treatment was given for up to six 21-day cycles. Bendamustine was omitted in three cases due to previous short-lived responses. Fourty-nine rrDLBCL(efficacy cohort-EC) and 58 rr aggressive B-NHL (safety cohort-SC) patients received at least 1 Pola-BR cycle. Twenty-one (43%) patients of the EC responded with 12/49 (25%) CR and 9/49 (18%) PR as best response. Median progression–free survival, overall survival and duration of response were 4.0, 8.5, and 8.5 months respectively, while 55% of patients experienced a grade ≥3 adverse event, mainly hematologic. Treatment discontinuations and death during treatment were mainly due to disease progression. Twenty-two (41%) patients received further treatment; 11/22 are still alive, including one after CAR-T cells, and two after stem cell transplantation. Our data confirm that Pola-BR is a promising treatment for rrDLBCL patients, inducing an adequate response rate with acceptable toxicity. Pola-BR could be used as bridging therapy before further consolidative treatments. © 2021 John Wiley & Sons Ltd.
Συγγραφείς:
Dimou, M.
Papageorgiou, S.G.
Stavroyianni, N.
Katodritou, E.
Tsirogianni, M.
Kalpadakis, C.
Banti, A.
Arapaki, M.
Iliakis, T.
Bouzani, M.
Verrou, E.
Spanoudakis, E.
Giannouli, S.
Marinakis, T.
Mandala, E.
Mparmparousi, D.
Sachanas, S.
Dalekou-Tsolakou, M.
Hatzimichael, E.
Vadikolia, C.
Violaki, V.
Poziopoulos, C.
Tsirkinidis, P.
Chatzileontiadou, S.
Vervessou, E.
Ximeri, M.
Sioni, A.
Konstantinidou, P.
Kyrtsonis, M.-C.
Siakantaris, M.P.
Angelopoulou, M.K.
Pappa, V.
Konstantopoulos, K.
Panayiotidis, P.
Vassilakopoulos, T.P.
Λέξεις-κλειδιά:
bendamustine; blinatumomab; bortezomib; brentuximab vedotin; cyclophosphamide plus doxorubicin plus etoposide plus prednisolone plus rituximab plus vincristine; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; ibrutinib; ifosfamide; lenalidomide; nivolumab; pixantrone; polatuzumab vedotin; rituximab; selinexor; antibody conjugate; antineoplastic agent; bendamustine; monoclonal antibody; polatuzumab vedotin; rituximab, adult; aged; Article; autologous stem cell transplantation; B cell lymphoma; cancer combination chemotherapy; cancer radiotherapy; cancer recurrence; cancer regression; chimeric antigen receptor T-cell immunotherapy; chronic obstructive lung disease; cohort analysis; colitis; consolidation chemotherapy; controlled study; disease exacerbation; drug efficacy; drug safety; drug withdrawal; febrile neutropenia; female; follow up; Greece; histology; human; intention to treat analysis; lung mycosis; major clinical study; male; neutropenia; overall response rate; overall survival; personal experience; pneumonia; progression free survival; rash; sensory neuropathy; stem cell transplantation; stomatitis; thrombocytopenia; treatment duration; treatment outcome; treatment response; B cell lymphoma; disease free survival; epidemiology; middle aged; mortality; survival rate; very elderly, Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Greece; Humans; Immunoconjugates; Lymphoma, B-Cell; Male; Middle Aged; Rituximab; Survival Rate
